Wintermute Biomedical Inc
Wintermute is a US/Australian company with a proprietary technology that harnesses the therapeutic properties of fatty acids. The company has completed a Phase Ib RCT of its lead product Solexan, a topical treatment for shingles with a novel antiviral mechanism of action. Wintermute has a library of antimicrobial compounds based on unique ammonium carboxylate salt technology that forms antimicrobial micelles. These micelles have very low toxicity and demonstrate efficacy against all types of bacteria, fungus and viruses.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}